X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/03/25/2851698/8339/en/Cassava-Sciences-Announces-Completion-of-an-Interim-Safety-Review-of-Oral-Simufilam-On-going-Phase-3-Trials.html
https://www.globenewswire.com//news-release/2023/11/06/2774211/8339/en/Cassava-Sciences-Completes-Enrollment-for-Pivotal-Phase-3-Program-of-Simufilam-in-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2023/10/25/2766625/8339/en/MRI-Data-Suggest-Simufilam-is-Not-Associated-with-Amyloid-related-Imaging-Abnormalities-ARIA.html
https://www.globenewswire.com//news-release/2023/10/02/2752815/8339/en/Cassava-Sciences-Completes-Patient-Enrollment-for-Pivotal-Phase-3-Clinical-Trial-of-Oral-Simufilam-in-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2023/09/18/2744877/8339/en/Cassava-Sciences-Announces-Positive-Interim-Safety-Review-of-Simufilam-On-going-Phase-3-Trials-in-Patients-with-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2023/09/11/2740891/8339/en/Cassava-Sciences-Announces-Science-Publication-That-Confirms-Mechanism-of-Action-of-Simufilam-a-Novel-Drug-Candidate-for-People-with-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2023/07/05/2699596/8339/en/Oral-Simufilam-Slowed-Cognitive-Decline-in-a-Randomized-Withdrawal-Trial-of-Mild-to-Moderate-Alzheimer-s-Disease.html
https://www.fool.com/investing/2023/05/12/why-shares-of-cassava-sciences-jumped-this-week/
https://www.globenewswire.com/news-release/2023/05/11/2666832/8339/en/Cassava-Sciences-Completes-Patient-Dosing-in-a-Randomized-Controlled-Trial-of-Simufilam-in-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2023/02/08/2604083/8339/en/Cassava-Sciences-Announces-Patient-Enrollment-Update-for-Phase-3-Studies-of-Simufilam-for-the-Treatment-of-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2023/01/24/2594355/8339/en/Cassava-Sciences-Announces-Positive-Top-Line-Clinical-Results-in-Phase-2-Study-Evaluating-Simufilam-in-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2022/12/06/2568442/8339/en/Cassava-Sciences-Announces-Completion-of-Dosing-in-Open-label-Study-of-Simufilam-for-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2022/10/13/2533980/8339/en/Cassava-Sciences-Announces-Initiation-of-an-Open-label-Extension-Study.html
https://www.globenewswire.com/news-release/2021/12/23/2357426/8339/en/Cassava-Sciences-Launches-Clinical-Website-to-Support-Phase-3-Studies-of-Oral-Simufilam-in-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2021/12/23/2357426/8339/en/Cassava-Sciences-Launches-Clinical-Website-to-Support-Phase-3-Studies-of-Oral-Simufilam-in-Alzheimer-s-Disease.html
https://www.fiercebiotech.com/biotech/federal-investigation-doesn-t-deter-cassava-from-starting-a-second-phase-3-trial-criticized
https://endpts.com/cassavas-problems-just-got-much-worse-as-sec-launches-probe-into-data-manipulation-claims-report/
https://endpts.com/cassava-being-investigated-by-unnamed-government-agencies-rocket-pharma-gives-updated-data-on-danon-disease/
https://www.fiercebiotech.com/biotech/cassava-drops-interim-alzheimer-s-data-plenty-caveats
https://www.globenewswire.com/news-release/2021/09/22/2301328/8339/en/Cassava-Sciences-Announces-Top-line-Results-of-12-month-Interim-Analysis-from-Open-label-Study-Evaluating-Simufilam-in-Alzheimer-s-Disease.html
Market Place
Share 
